Seattle, WA Juni 10, 2004 – Der US-. Patentamt erteilten Patent mit der Nummer 6,630,511, mit dem Titel "Wasser-Salze der 2-Difluormethyl-2 ,5-diaminopentanoic (GAF) bei Rolland Hebert von Seattle. Das Patent Ausgabe Oktober 7, 2003, enthüllt neue Zusammensetzungen, umfassend AGFA und Chitosan. Die FDA hat DFMO genehmigt, bekannt auch als EFLOrnithin zur Behandlung von Hirsutismus (übermäßige Gesichtsbehaarung) bei Frauen. AGFA ein Inhibitor der Ornithin Decarboxylase, ist auch in einem fortgeschrittenen Stadium der klinischen Studien zur Prävention von Brustkrebs untersucht, Dickdarm-und Hautkrebs.

AGFA is an irreversible inhibitor of Ornithin Decarboxylase (ODC), responsible for the conversion of L-Ornithin into putrescine, which in turn is converted more chain polyamines such as spermidine and the barrier required for the mine cell proliferation. inhibiting ODC, AGFA suppresses the formation of polyamines and thus cell proliferation. Since DFMO can suppress the formation of polyamines, may be able to suppress cell proliferation and, ultimately, improve or prevent cancer.

Ornithin is also important for the growth cycle of hair and a change of activity of ODC, the rate and character of hair growth may be affected. The first indication Current clinical use of DFMO for the treatment of hirsutism in women. Aber, a more general question is the use of DFMO to the growth of unwanted hair growth in men can reduce or even be used as a substitute for the razor to her control of the face. The chitosan DFMO new compositions, the irritation associated with topical application of GAF, a very significant improvement on the current market AGFA product called Vaniqa.

Vaniqa Cream is the first prescription, and only shown to slow the growth of unwanted facial hair (hirsutism) bei Frauen. Aber, the new DFMO chitosan composition offers an alternative called DFMO Vaniqa without burning and irritation associated with Vaniqa. The FDA requires Phase III clinical trials to demonstrate efficacy, and the new composition chitosan DFMO for approval. Questions concerning the co-development of DFMO with chitosan for use as growth or agent for chemoprevention of cancer inhibiting welcomed.

Contact Person: Rolland Hebert427 Bellevue Ave E. Following 301Seattle, WA 98102Telephone: 206.650.4489

Tags : Lage unterdrücken, Anwendung dfmo, Zellproliferation, dfmo Chitosan, Gesichtsbehaarung, Wachstum unerwünschter, Haarwachstum, Reizung verbunden, Ornithindecarboxylase, Rolland Hebert
Kategorien : Gesundheit & Fitness